Vator Securities: Advises Amniotics on 36 MSEK Rights Issue

Vator Securities: Advises Amniotics on 36 MSEK Rights Issue

• Vator Securities focuses on identifying and financing growth companies as they expand and develop into tomorrow’s market leaders
• Amniotics is a biopharma company focusing on mesenchymal stem cells (MSC) from amniotic fluid
• The company was born out of the discovery of a novel source of stem cells in full-term amniotic fluid
• Based on a decade of research at the internationally recognized Lund University Stem Cell Centre and the Skåne University Hospital of Lund
• The company is pioneering the harvesting and propagation of tissue-specific neonatal quality mesenchymal stem cells (MSC)
• Amniotics has also an, by Läkemedelsverket, approved GMP facility to produce Advanced Therapy Medicinal Products (ATMPs)